Evidence map›Paper›PMID 36399516›Full record

SynthesisBlood advances2023

Genome-wide meta-analysis identifies new candidate genes for sickle cell disease nephropathy.

Melanie E Garrett, Karen L Soldano, Kyle N Erwin, Yingze Zhang, Victor R Gordeuk, Mark T Gladwin, Marilyn J Telen, Allison E Ashley-Koch

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 3 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Management of Kidney Disease with Sickle Cell Disease.Journal of the American Society of Nephrology : JASN · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Melanie E GarrettDuke Molecular Physiology Institute, Duke University Medical Center, Durham, NC.ORCID 0000-0003-2302-6150
Karen L SoldanoDuke Molecular Physiology Institute, Duke University Medical Center, Durham, NC.ORCID 0000-0003-0326-8443
Kyle N ErwinDuke Molecular Physiology Institute, Duke University Medical Center, Durham, NC.ORCID 0000-0002-3725-3154
Yingze ZhangDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.ORCID 0000-0001-6947-2901
Victor R GordeukUniversity of Illinois at Chicago, Chicago, IL.ORCID 0000-0003-4725-7295
Mark T GladwinDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.ORCID 0000-0001-7267-9006
Marilyn J TelenDivision of Hematology, Department of Medicine, Duke University Medical Center, Durham, NC.ORCID 0000-0003-3809-1780
Allison E Ashley-KochDuke Molecular Physiology Institute, Duke University Medical Center, Durham, NC.ORCID 0000-0001-5409-9155
Duke Medical Center · USUniversity of Pittsburgh · USUniversity of Illinois Chicago · US

Funding

Pulmonary Hypertension in SCDR01HL079915 · NHLBI · DUKE UNIVERSITY · PI TELEN, MARILYN J · 2005 to 2008
$6.7M
Outcome Modifying Genes in Sickle Cell DiseaseR01HL068959 · NHLBI · DUKE UNIVERSITY · PI TELEN, MARILYN J · 2001 to 2005
$3.6M
Etiology of Congenital Heart Disease in Down SyndromeR01HL124836 · NHLBI · UNIVERSITY OF CHICAGO · PI MOSKOWITZ, IVAN PAUL, REEVES, ROGER H · 2014 to 2017
$2.7M
Transcriptomic, therapeutic and genetic investigations of sickle cell nephropathyR01DK110104 · NIDDK · DUKE UNIVERSITY · PI ASHLEY-KOCH, ALLISON E, DAVIS, ERICA ELLEN · 2016 to 2018
$716k
Identifying novel clinical, genetic and proteomic risk factors for sickle cell nephropathy.R21DK124836 · NIDDK · DUKE UNIVERSITY · PI ASHLEY-KOCH, ALLISON E · 2021 to 2022
$443k
NHLBI NIH HHS R01 HL068959NHLBI NIH HHS R01 HL079915NHLBI NIH HHS R01 HL124836NIDDK NIH HHS R01 DK110104NIDDK NIH HHS R21 DK124836
6 · The paper itself

Abstract

Sickle cell disease nephropathy (SCDN), a common SCD complication, is strongly associated with mortality. Polygenic risk scores calculated from recent transethnic meta-analyses of urinary albumin-to-creatinine ratio and estimated glomerular filtration rate (eGFR) trended toward association with proteinuria and eGFR in SCD but the model fit was poor (R2 < 0.01), suggesting that there are likely unique genetic risk factors for SCDN. Therefore, we performed genome-wide association studies (GWAS) for 2 critical manifestations of SCDN, proteinuria and decreased eGFR, in 2 well-characterized adult SCD cohorts, representing, to the best of our knowledge, the largest SCDN sample to date. Meta-analysis identified 6 genome-wide significant associations (false discovery rate, q ≤ 0.05): 3 for proteinuria (CRYL1, VWF, and ADAMTS7) and 3 for eGFR (LRP1B, linc02288, and FPGT-TNNI3K/TNNI3K). These associations are independent of APOL1 risk and represent novel SCDN loci, many with evidence for regulatory function. Moreover, GWAS SNPs in CRYL1, VWF, ADAMTS7, and linc02288 are associated with gene expression in kidney and pathways important to both renal function and SCD biology, supporting the hypothesis that SCDN pathophysiology is distinct from other forms of kidney disease. Together, these findings provide new targets for functional follow-up that could be tested prospectively and potentially used to identify patients with SCD who are at risk, before onset of kidney dysfunction.

Indexed as

Anemia, Sickle CellKidney DiseasesVascular DiseasesADAMTS7 ProteinAdultApolipoprotein L1Genome-Wide Association StudyHumansProtein Serine-Threonine KinasesProteinuriavon Willebrand FactorADAMTS7 ProteinAPOL1 protein, humanApolipoprotein L1Protein Serine-Threonine KinasesTNNI3K protein, humanvon Willebrand Factor

Identifiers

PMID36399516
PMCPMC10469559
OpenAlexW4309306160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.